Why Global Pharma Companies Are Moving API Sourcing from China to India

  • Home
  • Why Global Pharma Companies Are Moving API Sourcing from China to India
Split image depicting the shift in pharmaceutical API sourcing from China to India

16Apr

For decades, China’s dominance in Active Pharmaceutical Ingredient (API) manufacturing looked unassailable. Low-cost production and massive scale made it the default choice for global procurement teams. But geopolitical tensions, pandemic-era supply shocks, and sweeping tariffs have forced boardrooms to confront a critical vulnerability: what happens when a single country controls the inputs to your most vital products?

For a growing number of pharma companies, the answer involves transitioning supply chains to India.

What Is Driving the Shift?

The COVID-19 pandemic did not create the fragility in global pharma supply chains it simply made it impossible to ignore. When Chinese manufacturing hubs faced disruptions, API supply lines froze, and prices for key intermediates spiked.

This concentration risk is structural. In 2023–24, India imported approximately Rs 377 billion in APIs and bulk drugs, with China accounting for around 70% of that total. Procurement teams who once chose suppliers purely on price are now factoring in customs delays, tariff exposure, and the inherent risk of single-source dependency.

Why India Is a Viable Alternative

India offers a mature, government-backed manufacturing ecosystem that already supplies 20% of global generic drug demand. According to the India Brand Equity Foundation (IBEF), India ranks as the third-largest pharmaceutical producer by volume globally.

On regulatory standing, India supplies APIs to more than 200 nations and accounts for 57% of the APIs on the World Health Organization’s (WHO) prequalified list. Government policy is further accelerating this capacity; the Production-Linked Incentive (PLI) scheme has drawn substantial investments to promote domestic API self-reliance and expand the local CDMO market.

The Risk That Remains: Backward Integration

Simply switching from a Chinese supplier to an Indian one does not automatically remove supply chain risk. Because India still depends on China for a significant portion of its bulk drug and intermediate imports, treating geography as a proxy for security is a mistake.

The critical distinction for procurement teams is backward integration. Indian manufacturers who invest in domestic Key Starting Material (KSM) production and in-house synthesis offer genuine supply chain security compared to those who merely import and repackage Chinese feedstocks.

Evaluating an Indian API Intermediate Supplier

Rigorous supplier qualification is the only way to ensure a China+1 strategy actually delivers resilience. Here is what separates a reliable manufacturing partner from a basic database entry:

  • Analytical Purity & Transparency: Credible manufacturers provide batch-specific Certificate of Analysis (COA) data. For pharma intermediates, 99% purity is the baseline, not a premium feature.
  • Regulatory Track Record: Look for clean inspection histories from international bodies (USFDA, EMA, WHO). Cross-jurisdictional compliance indicates a functioning quality management system, not just a paper one.
  • KSM Sourcing Resilience: Ask suppliers directly to map their KSM origins and outline their contingencies for primary source disruptions.
  • Proven Scale-Up Capacity: Lab-scale success does not guarantee commercial viability. Verify their installed capacity, utilization rates, and past performance in scaling specific chemical reactions.
  • Communication Speed: In a disruption, technical credibility and honest lead times matter more than initial price. Ask for customer references specifically regarding how the supplier handles delays.

The Next Step for Procurement Teams

The shift toward Indian intermediate sourcing requires technical diligence, not just aggressive price negotiation. Building a resilient supply chain means identifying partners with verified analytical rigor and genuine backward integration.

Advance Pharma Chem operates a specialty chemical manufacturing facility in Ambernath MIDC, producing high-purity pharmaceutical intermediates including 7-Chloroquinaldine and Isatin. The facility operates on a model of domestic KSM sourcing and batch-specific analytical verification.

👉Request Batch-Specific HPLC Chromatograms and full CoAs
👉Download Our Full 2026 Product Catalog

Frequently Asked Questions

Q1. Why are global pharma companies reducing their dependence on China for API sourcing?

The primary drivers are structural supply chain vulnerabilities, escalating US Section 301 tariffs, and geopolitical volatility. The pandemic proved that geographic concentration in API inputs can halt downstream drug manufacturing. Consequently, procurement teams are shifting from price-exclusive sourcing models to risk-adjusted multi-source strategies, heavily favoring India’s established infrastructure.

Q2. Is India truly independent of China for pharmaceutical raw materials?

No. India currently imports approximately 70% of its bulk drugs and intermediates from China. True supply chain diversification requires evaluating individual suppliers rather than geographic regions. Procurement teams must verify a supplier’s level of backward integration and their domestic sourcing of Key Starting Materials (KSMs).

Q3. What purity standards should I expect from a qualified Indian pharmaceutical intermediate supplier?

For pharmaceutical-grade intermediates, the baseline specification is ≥99% purity, typically verified via Gas Chromatography (GC) or High-Performance Liquid Chromatography (HPLC). Qualified suppliers must supply batch-specific Certificate of Analysis (COA) documentation, detailing not just the headline purity, but also exact impurity profiles, moisture content, and isomer controls where applicable.

Q4. How long does it typically take to qualify a new Indian supplier for pharma intermediates?

A rigorous qualification process typically spans three to six months. This timeline accounts for initial document review (COAs, spectra data), independent analytical testing of samples, a facility audit (virtual or on-site), and the completion of technical questionnaires assessing synthesis routes and QMS infrastructure.

Q5. What makes specialty chemical manufacturers in India different from bulk generic API producers?

Bulk generic API producers compete primarily on volume and scale for standardized molecules. In contrast, specialty chemical manufacturers focus on complex, lower-volume intermediates requiring multi-step synthesis, advanced isomer separation, and highly controlled reaction environments. They are evaluated on technical process expertise rather than pure tonnage.

References & Citations